Sohaei Dorsa, Thebault Simon, Avery Lisa M, Batruch Ihor, Lam Brian, Xu Wei, Saadeh Rubah S, Scarisbrick Isobel A, Diamandis Eleftherios P, Prassas Ioannis, Freedman Mark S
Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Canada.
Department of Medicine, The Ottawa Hospital, 01 Smyth Road, Box 601, Ottawa, ON, K1H 8L6, Canada.
Clin Proteomics. 2023 Aug 29;20(1):33. doi: 10.1186/s12014-023-09418-9.
Multiple sclerosis (MS) remains a highly unpredictable disease. Many hope that fluid biomarkers may contribute to better stratification of disease, aiding the personalisation of treatment decisions, ultimately improving patient outcomes.
The objective of this study was to evaluate the predictive value of CSF brain-specific proteins from early in the disease course of MS on long term clinical outcomes.
In this study, 34 MS patients had their CSF collected and stored within 5 years of disease onset and were then followed clinically for at least 15 years. CSF concentrations of 64 brain-specific proteins were analyzed in the 34 patient CSF, as well as 19 age and sex-matched controls, using a targeted liquid-chromatography tandem mass spectrometry approach.
We identified six CSF brain-specific proteins that significantly differentiated MS from controls (p < 0.05) and nine proteins that could predict disease course over the next decade. CAMK2A emerged as a biomarker candidate that could discriminate between MS and controls and could predict long-term disease progression.
Targeted approaches to identify and quantify biomarkers associated with MS in the CSF may inform on long term MS outcomes. CAMK2A may be one of several candidates, warranting further exploration.
多发性硬化症（MS）仍然是一种高度不可预测的疾病。许多人希望体液生物标志物可能有助于更好地对疾病进行分层，辅助治疗决策的个性化，最终改善患者的预后。
本研究的目的是评估MS疾病早期脑脊液中脑特异性蛋白对长期临床结局的预测价值。
在本研究中，34例MS患者在疾病发作5年内收集并储存脑脊液，然后进行至少15年的临床随访。使用靶向液相色谱串联质谱法分析了34例患者脑脊液以及19例年龄和性别匹配的对照中64种脑特异性蛋白的脑脊液浓度。
我们鉴定出六种脑脊液脑特异性蛋白，它们能显著区分MS患者与对照组（p < 0.05），还有九种蛋白可以预测未来十年的疾病进程。钙/钙调蛋白依赖性蛋白激酶2A（CAMK2A）成为一种生物标志物候选物，它可以区分MS患者与对照组，并能预测长期疾病进展。
在脑脊液中识别和量化与MS相关生物标志物的靶向方法可能有助于了解MS的长期结局。CAMK2A可能是众多候选物之一，值得进一步探索。
